Current oncology最新文献

Background/objectives: Cervical cancer outcomes based on geographic location of residence reveal inconsistent patterns, and most of the evidence is from the United States. This retrospective study aimed to investigate whether there existed a difference in overall survival (OS) and recurrence-free survival (RFS) between individuals living within a Canadian city with a tertiary care centre versus those living remotely within a large catchment area (up to >1000 km travel distance), including a sizeable rural component.

Methods: Surgically treated cervical cancer patients from 2000 to 2016 were included. Patients were treated with either radical hysterectomy, trachelectomy, or simple hysterectomy. Adjuvant treatment was provided depending on surgical pathology. OS and RFS were estimated using Kaplan-Meier curves and cumulative incidence curves.

Results: Two hundred and eighty-two patients with surgically treated cervical cancer were included: 185 patients living within urban city limits and 97 patients living rurally. There were no significant baseline differences between groups. No significant difference in OS or RFS was found, even after adjusting for death as a competing risk for RFS. The median time to surgery for residents living within versus outside the city was 84 vs. 66 days, respectively, although this difference was not statistically significant (p = 0.3179).

Conclusions: This is the first Canadian study to examine an association between survival and distance to care for cervical cancer.

Adolescents and Young adults (AYAs: 15-39 years) diagnosed with cancer face unique medical and psychosocial challenges requiring specialized care. This study conducted an environmental scan of AYA-specific programming and services currently offered across Canadian tertiary care centres. Key informants from pediatric and adult cancer centres in Canada reported on program logistics, AYA specialized staff and training opportunities, and collaboration between centres, funding, and specific areas of interest for AYA care such as palliative care, fertility, fatigue, and sexual health. Surveys were completed by 13/16 (81%) pediatric sites and 19/23 (83%) adult sites. Only about half of pediatric sites (n = 8/13) and adult sites (n = 9/19) who responded reported offering any AYA-specific cancer services or programming. One third of centres without programming reported to be working on developing programming. Only 6 sites reported to offer specialized AYA training. Several barriers were reported, such as the need for collaboration among institutions and improvement of oncofertility services. Significant disparities exist regarding geographic availability of services, the range of services available, and the populations served. Findings will guide researchers, health professionals, and provincial health authorities in the development of highquality and equitable services and programs for AYAs diagnosed with cancer across Canada.

Our objective was to conduct a scoping review and narrative synthesis of qualitative studies that examined experiences of partners of cancer patients. We searched MEDLINE, Embase, CINAHL, PsycINFO, and Scopus for qualitative studies involving adult (≥18 years) partners (e.g., in a romantic relationship) of patients diagnosed with cancer and published in English. We extracted findings from included studies, along with key study and participant characteristics, and applied a narrative summary approach, a process that allowed us to identify synthesized themes across studies. Our search identified 15,729 records, of which 159 met the inclusion criteria. Included studies primarily collected data through interviews, with participants being predominantly female and middle-aged (55.2 ± 8.3 years). Partners were commonly in relationships with patients diagnosed with breast, genital-urinary, or gastrointestinal cancer. Our synthesis identified four conceptual themes-transformation of relationship dynamics and roles, distress and burden, coping strategies, and unmet needs and support gaps-which reflect the emotional, relational, and practical challenges partners navigate throughout the cancer trajectory. These findings highlight the need to better recognize and support the role of partners within the cancer care landscape as their wellbeing impacts care and experiences of patients with cancer.

High-risk benign breast lesions are histological abnormalities that present in breast tissue, typically identified by screening or diagnostic imaging. The presence of invasive or in situ breast cancer can be confirmed or ruled out within these lesions, and the risk of developing breast cancer can be reduced by their appropriate management. These potential high-risk lesions reviewed include atypical ductal hyperplasia, mucocele-like lesions, papillary lesions with or without atypia, radial scar/complex sclerosing lesion with or without atypia, atypical lobular hyperplasia, classical lobular carcinoma in situ, pleomorphic/florid lobular carcinoma in situ, flat epithelial atypia, columnar cell change, fibroepithelial lesions with stromal cellularity, spindle cell lesions/mesenchymal lesions, and microglandular adenosis. The lack of a clear consensus on the management of many of these lesions led the Ontario Health (Cancer Care Ontario) (OH-CCO) Breast Cancer Pathway Map Working Group and Breast Cancer Advisory Committee to identify the need for a recommendation document. A multidisciplinary working group was formed, with members representing surgical oncology, radiology, pathology, medical oncology, and genetic counselling. The working group developed a list of high-risk benign lesions to be included in this recommendation report. An updated literature review was completed, and these publications were reviewed by the working group, and recommendations were drafted. When evidence was lacking, the expert opinion was included. These draft recommendations were subjected to an extensive review by experts both within Cancer Care Ontario and across Canada. The recommendations included in this report are relevant to clinicians, primary care physicians, oncologists, radiologists, and pathologists who treat breast cancer and manage breast conditions.

Background: Comprehensive genomic profiling (CGP) is a tool used in precision oncology to identify genomic alterations and match them with targeted therapies across several tumor types. However, real-world data on its clinical utility and impact remains limited. The FRONTAL study (Foundation Medicine Real wOrld evideNce in porTugAL) is a multicenter academic initiative that established a national registry of Portuguese patients with solid tumors who underwent CGP with FoundationOne CDx, Liquid CDx or FoundationOne Heme assays. Methods: Eligible patients had advanced solid tumors not suitable for curative treatment at the time of recruitment. Prior CGP testing was permitted if taken within 12 months before study initiation. Genomic profiling data were extracted from FoundationOne Medicine reports, and clinical information was extracted from medical records. Actionable alterations were defined as those associated with approved treatments or with clinical evidence of benefit in other cancers, per NCCN guidelines. Variant interpretation was also reviewed according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) guidelines. The primary outcome was disease control at 16 weeks, defined by the absence of progression. Results: The study included 205 patients between 2020 and 2025 across 10 sites, with colorectal (40, 19.5%), sarcomas (28, 13.7%), and other gastrointestinal tumors (22, 10.7%) being the most common pathologies. Actionable alterations were identified in 104 cases (50.7%). Genomic findings guided therapy decisions in 50 patients (24.4%), of whom 30 achieved disease control at 16 weeks (14.6%). Conclusions: The FRONTAL study highlighted the clinical relevance of CGP in advanced solid tumors. Over half of the patients had actionable alterations, a quarter had therapy changes based on CGP results, and improved disease outcome was observed in approximately 15% of the cohort.

Background: Artificial intelligence (AI) and machine learning (ML) are increasingly used in the diagnosis and management of bone metastases, spanning lesion detection, segmentation, prognostic modeling, fracture risk assessment, and surgical decision support. However, the literature is heterogeneous and rapidly evolving, making it difficult for clinicians to contextualize these developments.

Methods: We performed a narrative review of the literature on AI/ML applications in bone metastasis management, focusing on studies that address clinically relevant problems such as detection and segmentation of metastatic lesions, prediction of skeletal-related events and survival, and support for reconstructive decision-making. We prioritized recent, peer-reviewed work that reports model performance and highlights opportunities for clinical translation.

Results: Most published studies center on imaging-based diagnosis and lesion segmentation using radiomics and deep learning, with generally high internal performance but limited external validation. Emerging work explores prognostic models and biomechanically informed fracture risk estimation, yet these remain at an early proof-of-concept stage. Very few frameworks are integrated into routine workflows, and explainability, bias mitigation, and health-economic impacts are rarely evaluated.

Conclusions: AI and ML tools have substantial potential to standardize imaging assessment, refine risk stratification, and ultimately support personalized management of bone metastases. Future research should focus on externally validated, multimodal models; development of AI-augmented alternatives to the Mirels score; federated multicenter collaboration; and routine incorporation of explainability and cost-effectiveness analyses.

Anal squamous cell carcinoma (ASCC) is a rare malignancy of the lower gastrointestinal tract, with distant metastases typically involving the liver and lungs. Metastasis to the kidneys is uncommon, and only one prior case has been reported in the literature. Herein, we report a rare presentation of a patient with biopsy-confirmed metastatic ASCC presenting as bilateral renal lesions. We then provide a review of the literature for rare metastatic presentations of ASCC, highlighting all the cases described in the literature. Clinicians should maintain a high index of suspicion for unusual metastatic sites, perform targeted imaging and biopsy when indicated, and consider systemic therapies to optimize outcomes in rare metastatic presentations.

Open partial horizontal laryngectomy (OPHL) is a key conservative option for laryngeal cancer, with established oncological outcomes but limited data on functional results and patient perspectives. Voice preservation is mainly associated with type I OPHL, whereas types II-III often result in significant but broadly comparable impairments, making vocal decline the main limitation of OPHL. Patient-reported outcomes (PROs) help clarify the balance between treatment efficacy and side effects. This single-institution study analyzed 70 consecutive OPHL patients (12 women, 17.1%; 58 men, 82.9%), mean age 65.9 years (SD 8.96), with a median follow-up of 52.5 months (range 2-218). PROs were assessed using the Priority Scale, the V-RQOL, the MDADI, the Decisional Conflict Scale, the Decisional Regret Scale, and the Brief Pain Inventory. The Priority Scale showed that curing cancer (98.6%) and prolonging life (82.9%) were top concerns, while only 34.3% prioritized natural voice preservation. V-RQOL averaged 77.4/100, indicating limited impact of voice on quality of life; MDADI was 78.5/100, reflecting minimal swallowing difficulties. Decisional Conflict averaged 34.3/100, with 30% reporting no difficulty; Decisional Regret was low (13.0/100), with only 1.4% expressing moderate regret. Most patients (78.6%) reported no pain. Overall, OPHL provided satisfactory functional and decisional outcomes, with high patient satisfaction despite the complexity of treatment.

Background/Objectives: Holocord astrocytomas are exceptionally rare intramedullary tumors, especially in adults, and often present with extensive longitudinal growth. Because only a small number of cases have been described, management strategies remain insufficiently defined. This report presents an adult patient treated with a staged surgical approach and provides an updated review of the literature. Methods: A 31-year-old male presented with progressive paraparesis, sensory deficits, and sphincter dysfunction. MRI demonstrated an intramedullary tumor extending from T3 to the conus medullaris. The patient underwent a planned two-stage resection with intraoperative neurophysiological monitoring. Histopathological and DNA-methylation analyses were performed. Additionally, a systematic review of previously reported holocord astrocytoma cases was conducted. Results: The two-stage surgical strategy enabled extensive debulking across multiple spinal segments while preserving neurological function. The patient demonstrated marked postoperative improvement, including restoration of sphincter control, improved motor function, and better mobility. Histopathological analyses confirmed a high-grade astrocytoma with piloid features. The literature review identified 28 previously reported cases, including only 5 in adults. Reported neurological outcomes across adult cases are variable, reflecting the heterogeneity and rarity of this tumor entity. Conclusions: Holocord astrocytomas in adults are extremely rare and pose particular diagnostic and therapeutic challenges. This case demonstrates that a carefully planned, staged surgical approach can achieve meaningful neurological recovery, even in patients presenting with severe preoperative deficits. The report expands the limited body of evidence available for adult holocord astrocytomas and may support future management strategies.

Many children with cancer referred to physical therapy (PT) do not attend the service. We conducted a pilot study, comprising a cross-sectional survey and interviews with parents of children with acute lymphoblastic leukemia. The survey explored parents' (1) views on PT service delivery for their child, (2) perspectives on barriers and facilitators, (3) preferred timing to introduce PT, and (4) views on virtual services. Questions were designed based on the Theoretical Domains Framework, and responses were mapped onto the Capability, Opportunity, Motivation-Behavior Change Model. Twenty parents participated in the survey. Although all parents would consider their child accessing PT if deficits were present, access depended on a convenient location (70%) and availability of virtual delivery (45%). While half of the parents preferred PT treatment to be introduced during the maintenance phase of chemotherapy, findings also support earlier introduction during the consolidation phase when services are framed as part of standard care. While most parents perceived that it would be manageable to support home-based PT, barriers included a lack of child's motivation without therapist support. Seven parents participated in semi-structured interviews. They identified time constraints, distance, and costs as common barriers. Most parents responded positively to hybrid PT models and connections with community locations to mitigate these challenges.